The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 construction jobs expected on the job site. The laboratory component of the new site ...